Purchased MDMA supply from PharmAla Biotech for upcoming IND-enabling studies Finalizing product and clinical development plans for upcoming studies and potential commercial opportunities TORONTO, April 03, 2023 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty pharmaceutical company, is pleased to announce the…

Source

Previous articleReunion Neuroscience Appoints Dr. Fred Grossman to Board of Directors
Next articlePsyence Group Announces Closing of Fourth Tranche of Private Placement and Conversion of Convertible Debt Note